Meeting
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
Authors
Christoffer Gebhardt
Skin Cancer Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Christoffer Gebhardt , Laura Keller , Isabel Heidrich , Julian Koett , Glenn Geidel , Charles Abbott , Sean Michael Boyle , Jason Pugh , Richard Chen , Ronald Simon , Stefan W. Schneider , Klaus Pantel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9562)
DOI
10.1200/JCO.2023.41.16_suppl.9562
Abstract #
9562
Poster Bd #
325
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).
First Author: Jenny HJ Lee
Poster
2024 ASCO Annual Meeting
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.
First Author: Alexandre Harle
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela